PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-168.99%
Negative EBIT growth while RVPH is at 5.85%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-230.56%
Negative operating income growth while RVPH is at 7.11%. Joel Greenblatt would press for urgent turnaround measures.
-176.90%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
89.62%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
89.62%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2567.99%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2567.99%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-298628.16%
Negative OCF growth while RVPH is at 38.83%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-217028.56%
Negative FCF growth while RVPH is at 38.83%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-67594.88%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-60146.79%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
-86002.39%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-51844.29%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-93706.66%
Negative 5Y net income/share CAGR while RVPH is 60.51%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-45701.99%
Negative 3Y CAGR while RVPH is 58.01%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
3346.07%
Equity/share CAGR of 3346.07% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1899.20%
Equity/share CAGR of 1899.20% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
720.41%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
104.51%
Asset growth above 1.5x RVPH's 64.40%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-98.43%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
92.16%
We have some new debt while RVPH reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-30.73%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
522.30%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.